Del Mar, California — November 25, 2025 — Leads & Copy — American Diversified Holdings Corporation (OTCID: ADHC) has announced that GlucoGuard has completed the Level 2 App integration through DEXCOM’s Developer Program.
The project development is in conjunction with UC Irvine’s MADO program through the California Institute for Telecommunications and Information Technology (CALIT2a).
The Dexcom Developer Program allows developers to access Dexcom API and integrate Dexcom CGM data into their applications. Dexcom partners gain access to app credentials, sandbox data, and development support. The Dexcom API allows partners to integrate DEXCOM CGM data, such as glucose levels, into their applications.
The next level of App integration development is expected to be approved in mid-June, resulting in a fully functional back-end to front-end completion where the app will run on a mobile device.
Developments include a functional front-end and back-end App capable of running on an emulator, a trained predictive algorithm for detecting hypoglycemia episodes with 95% accuracy, and secured Registered Developer access to the Dexcom API, enabling initial integration with continuous glucose monitoring (CGM) data.
GlucoGuard is also developing a suite of AI features to predict negative blood glucose events and mitigate these events before the patient suffers catastrophic adverse effects. The ability to manage glucose in this manner is a groundbreaking advancement that will establish GlucoGuard as a revolutionary technology in the field of diabetes, a multibillion-dollar industry.
ADHC commented that they are very appreciative to all their partners in reaching these milestones, stating that developments are progressing rapidly and the GlucoGuard team is very grateful for the amazing support from all of their stakeholders.
GlucoGuard is a medical device company developing GlucoGuard, a patent-pending nocturnal glucose monitoring and delivery system for diabetic patients. The system helps prevent the dangerous effects of hypoglycemia “low blood sugar” during sleep, including the potentially fatal “Death in Bed” phenomenon. GlucoGuard combines advanced engineering, artificial intelligence (AI), and mobile app-based monitoring to create an innovative solution for managing nocturnal Hypoglycemia. The GlucoGuard mouthpiece continuously monitors glucose levels during sleep and automatically administers glucose when hypoglycemic levels are detected. Sophisticated AI algorithms facilitate this process, ensuring effective glucose management without disturbing the patient’s rest.
Arete Bio Sciences, Inc. maintains an extensive network of internal staff and collaborators with experience across device form factor exploration, rapid prototyping, and product visualization in the health space. The Arete Bio Science team of scientists, strategic thinkers, problem solvers, engineers, and innovators is passionate about creating a positive impact on global health. Projects include the design, development, and management of molecular diagnostic systems, molecular assays, start-ups, and build-ups of several companies, and have managed product development teams across four continents in seven countries.
Created in 2000, the California Institute for Telecommunications and Information Technology – known as CALIT2 – promotes discovery and innovation, harnessing the ubiquity and scale of the internet and wireless technologies to accelerate growth in many scientific areas and industries undergoing a massive transformation.
Dexcom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally, providing its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians.
The company markets its products directly to endocrinologists, physicians, and diabetes educators. Dexcom was incorporated in 1999 and is headquartered in San Diego, California.
Key Development Partnerships: The GlucoGuard system is being developed in collaboration with three key partners: UNIVERSITY OF CALIFORNIA IRVINE, ARETE BIOSCIENCE, and DEXCOM.
A recent report from the Mayo Clinic identified three potential benefits of AI in healthcare: Improving outcomes for both patients and clinical teams, lowering healthcare costs, and benefitting population health. From preventive screenings to diagnosis and treatment, AI is being used throughout the continuum of care today.
The diabetes market is poised for substantial growth, with the U.S. market valued at $28 billion, underscoring the vast potential for GlucoGuard’s adoption. The Continuous Glucose Monitoring (CGM) sector, valued at $6.8 billion, further emphasizes the critical demand for advanced glucose management solutions.
Contact: Phone: 817-525-0057, Email: info@GlucoGuardSleep.com
Source: GlucoGuard
